Palatin Technologies Inc.
09/22/2025 | Press release | Distributed by Public on 09/23/2025 09:16
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim (Form 8-K)
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal
Disease Collaboration with Boehringer Ingelheim
|
· |
Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic macular edema |
PRINCETON, NJ - September 22, 2025 - Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company advancing medicines that modulate the melanocortin receptor system, today announced the achievement of a research milestone under its collaboration with Boehringer Ingelheim. This milestone triggers a €5.5 million ($6.5 million) payment to Palatin.
"We are very pleased to reach this milestone and continue building momentum with Boehringer Ingelheim," said Carl Spana, Ph.D., President and CEO of Palatin. "Melanocortin receptor agonists represent a differentiated and promising approach to address the underlying drivers of retinal diseases such as diabetic retinopathy and diabetic macular edema, which affect an estimated one in three people living with diabetes."
About the Collaboration
On August 18, 2025, Palatin entered into a strategic partnership with Boehringer Ingelheim to develop potential first-in-class melanocortin receptor-targeted treatments for patients with retinal diseases. Under the terms of the agreement, Palatin has received an upfront payment of €2.0 million ($2.3 million) and is eligible for research, development, regulatory and commercial milestone payments of up to €278 million ($328 million), as well as tiered royalties on net sales.
About Melanocortin Receptor Agonists
The melanocortin receptor (MCR) system regulates inflammation, immune responses, and metabolism. Receptor-specific agonists represent a novel therapeutic approach with potential applications in multiple diseases, including retinal disorders.
About Palatin
Palatin is a biopharmaceutical company developing receptor-specific medicines targeting the melanocortin receptor system to treat diseases with significant unmet medical need. Palatin's strategy is to advance its pipeline of innovative melanocortin agonists through development and partner with leading pharmaceutical companies to expand patient access and maximize commercial potential.
For more information, visit www.Palatin.com or follow Palatin on X (formerly Twitter) at @PalatinTech.
Palatin Technologies Inc. published this content on September 22, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 23, 2025 at 15:18 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]